Ads
related to: Treatment Macular Degeneration- Wet AMD FAQs
Get Answers To Frequently Asked
Questions About Wet AMD
- Appointment Tips
Get Tips And Useful Information
To Talk to your Retina Specialist
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Wet AMD FAQs
Search results
EyePoint Pharmaceuticals stock target cut, retains Buy rating By Investing.com
Investing.com· 4 days agoThe reduction follows a significant 43% drop in EyePoint's share value on Monday, which contrasted...
Head to Head Survey: Cognition Therapeutics (NASDAQ:CGTX) vs. Opthea (NASDAQ:OPT)
ETF DAILY NEWS· 6 days agoCognition Therapeutics (NASDAQ:CGTX – Get Free Report) and Opthea (NASDAQ:OPT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the ...
A Dietician Explains the Difference Between Chlorella and Spirulina—Do You Know Which Is Healthier?
Health.com· 4 days agoSpirulina and chlorella are types of microalgae commonly taken in supplement form. They share some...
HC Wainwright Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)
ETF DAILY NEWS· 2 days agoHC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a research report report published on Monday, Benzinga reports. The firm currently ...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Benzinga· 4 days agoThe data demonstrated that Duravyu has a biologic effect in patients with NPDR and a favorable safety and tolerability profile; however, the trial did not meet the pre-specified primary endpoint ...
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Zacks· 4 days agoFree Report) incurred a first-quarter 2024 loss of 54 cents per share, which matched the Zacks Consensus Estimate. Total revenues amounted to $172.3 million in the reported quarter, beating ...
Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com
ETF DAILY NEWS· 7 days agoEquities researchers at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research note issued on Thursday. The brokerage set a “sell” rating ...
Ocular Therapeutix stock target cut, Buy rating kept By Investing.com
Investing.com· 3 days agoThe biopharmaceutical company, known for its eye care treatments, has recently disclosed its...
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World...
FOX 5 San Diego· 4 days agoDALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoGenerated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA
Ad
related to: Treatment Macular Degeneration
